Surveillance, Epidemiology, and Ends Results Program. Fast Stats. Available at: http://seer.cancer.gov/faststats/selections.php. Accessed March 11, 2014.
Heijnsdijk EA, Wever EM, Auvinen A et al.. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595–605.
Schroder FH, Hugosson J, Roobol MJ et al.. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen—based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013;158:145–153.
Hugosson J, Carlsson S, Aus G et al.. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–732.
Andriole GL, Crawford ED, Grubb RL 3rd et al.. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–132.
Andriole GL. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Recent Results Cancer Res 2014;202:53–57.
Crawford ED, Grubb R 3rd, Black A et al.. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011;29:355–361.
Bach PB, Vickers AJ. Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? J Clin Oncol 2011;29:e387.
Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009;169:1603–1610.
Lilja H, Cronin AM, Dahlin A et al.. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210–1219.
Vickers AJ, Ulmert D, Sjoberg DD et al.. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
Capitanio U, Perrotte P, Zini L et al.. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. Urology 2009;73:1323–1327.
Chun FK, Hutterer GC, Perrotte P et al.. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 2007;100:37–41.
Ulmert D, Cronin AM, Bjork T et al.. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008;6:6.
Sun L, Caire AA, Robertson CN et al.. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009;182:2242–2248.
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235–241.
Vickers AJ, Cronin AM, Bjork T et al.. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521.
Schaeffer EM, Carter HB, Kettermann A et al.. Prostate specific antigen testing among the elderly—when to stop? J Urol 2009;181:1606–1614.
van Leeuwen PJ, Roobol MJ, Kranse R et al.. Towards an optimal interval for prostate cancer screening. Eur Urol 2012;61:171–176.
Nam RK, Kattan MW, Chin JL et al.. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol 2011;29:2959–2964.
Thompson IM, Ankerst DP, Chi C et al.. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529–534.
Roobol MJ, Steyerberg EW, Kranse R et al.. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79–85.
Carter HB, Ferrucci L, Kettermann A et al.. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521–1527.
Partin AW, Brawer MK, Subong EN et al.. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998;1:197–203.
Bradley LA, Palomaki GE, Gutman S et al.. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013;190:389–398.
Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729–739.
Lazzeri M, Haese A, Abrate A et al.. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112:313–321.
- Search Google Scholar
- Export Citation
. Lazzeri M Haese A Abrate A Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013; 112: 313– 321.
Loeb S. Prostate cancer: Prostate Health Index—improving screening in men with family history. Nat Rev Urol 2013;10:497–498.
Catalona WJ, Partin AW, Sanda MG et al.. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650–1655.
- Search Google Scholar
- Export Citation
. Catalona WJ Partin AW Sanda MG A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650– 1655.
Vickers AJ, Gupta A, Savage CJ et al.. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255–261.